SEC Form 4 · accession 0001796436-26-000002
Elicio Therapeutics, Inc. · ELTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Connelly
Officer — CEO, President and Director · Director
Period of report
Jul 16, 2026
Accepted (ET)
Jul 17, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001601485
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.20 | Jul 16, 2026 | A | 186,944 | A | — | Jul 16, 2036 | Common Stock | 186,944 | 186,944 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.